Chimerix, Inc.
Chimerix, Inc. (CMRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cmrx · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Chimerix, Inc. (CMRX) measures how much investors pay for each dollar of the company's trailing earnings. CMRX's current PE ratio of N/A is calculated by dividing its stock price of $8.54 by its TTM earnings per share of -$0.99.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2010 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Chimerix, Inc.You CMRX | $801M | N/A | — | -$0.99 |
 Albireo Pharma, Inc. ALBO | $916M | N/A | — | -$7.87 |
 ASLAN Pharmaceuticals Limited ASLN | $777M | N/A | — | -$10.75 |
 Avid Bioservices, Inc. CDMO | $799M | N/A | — | -$2.23 |
 Gracell Biotechnologies Inc. GRCL | $198M | N/A | — | -$44.87 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
 Intercept Pharmaceuticals, Inc. ICPT | $795M | 3.63x | — | $3.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.99 | — | |
2023-12-31 FY2023 | — | $-0.93 | — | |
2022-12-31 FY2022 | 0.95x | $1.97 | — | |
2021-12-31 FY2021 | — | $-3.01 | — | |
2020-12-31 FY2020 | — | $-0.68 | — | |
2019-12-31 FY2019 | — | $-3.13 | — | |
2018-12-31 FY2018 | — | $-1.43 | — | |
2017-12-31 FY2017 | — | $-1.51 | — | |
2016-12-31 FY2016 | — | $-1.65 | — | |
2015-12-31 FY2015 | — | $-2.67 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Chimerix, Inc. (CMRX) measures how much investors pay for each dollar of the company's trailing earnings. CMRX's current PE ratio of N/A is calculated by dividing its stock price of $8.54 by its TTM earnings per share of -$0.99.
Frequently asked questions
CMRX pe ratio · 6 questionsCMRX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $8.54 and TTM EPS of -$0.99. Data sourced from Financial Modeling Prep via CMRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Chimerix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09